European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 141, Issue 2 , Pages 147-152 , December 2008

Characterization of breast cancer subtypes by quantitative assessment of biological parameters: Relationship with clinicopathological characteristics, biological features and prognosis

  • J.M. Del Casar

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • Servicio de Cirugía General, Hospital de Jove, Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
    • ,
  • A. Martín

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • ,
  • C. García

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • ,
  • M.D. Corte

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • ,
  • A. Alvarez

      Affiliations

    • Servicio de Medicina Nuclear, Hospital Central de Asturias, Oviedo, Spain
    • ,
  • S. Junquera

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • ,
  • L.O. González

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
    • Servicio de Anatomía Patológica, Hospital de Jove, Gijón, Spain
    • ,
  • M. Bongera

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • ,
  • J.L. García-Muñiz

      Affiliations

    • Servicio de Cirugía General, Hospital Central de Asturias, Oviedo, Spain
    • ,
  • M.T. Allende

      Affiliations

    • Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
    • Servicio de Medicina Nuclear, Hospital Central de Asturias, Oviedo, Spain
    • ,
  • F. Vizoso

      Affiliations

    • Unidad de Investigación, Hospital de Jove, Gijón, Spain
    • Servicio de Cirugía General, Hospital de Jove, Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
    • Corresponding Author InformationCorresponding author at: Hospital de Jove, Servicio de Cirugía General, Avda. Eduardo Castro s/n, Apartado 385, 33290 Gijón, Spain. Tel.: +34 985315710.

Received 6 July 2007 ,Revised 10 April 2008 ,Accepted 11 July 2008.

References 

  1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874
  2. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–8423
  3. Bertucci F, Viens P, Hingamp P, Nasser V, Houlgatte R, Birnbaum D. Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer. 2003;103:565–571
  4. van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  5. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–10398
  6. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991–1996
  7. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374
  8. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688–694
  9. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol. 2003;12:27–34
  10. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005;65:767–779
  11. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359–377
  12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem. 1976;72:248–254
  13. Hedley DW, Shankey TV, Wheeless LL. DNA cytometry consensus conference. Cytometry. 1993;14:471
  14. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest. 2002;82:1525–1533
  15. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–271
  16. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007;16:104–107
  17. Corte MD, Rodil JA, Vazquez J, et al. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). J Cancer Res Clin Oncol. 2005;131:701–714
  18. Quintela I, Corte MD, Allende MT, et al. Expression and prognostic value of EGFR in invasive breast cancer. Oncol Rep. 2005;14:1655–1663
  19. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34
  20. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502
  21. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  22. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002;13:1977–2000
  23. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10–21
  24. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61:203–212
  25. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci. 1994;19:459–463
  26. Velu T, Beguinot L, Vass W, et al. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science. 1987;238:1408–1410
  27. Di Marco E, Pierce J, Fleming T, et al. Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene. 1989;4:831–838
  28. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241–250
  29. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005;65:9155–9158
  30. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127
  31. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–5685
  32. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005;65:2170–2178
  33. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652–1654

PII: S0301-2115(08)00284-4

doi: 10.1016/j.ejogrb.2008.07.021

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 141, Issue 2 , Pages 147-152 , December 2008

Article Tools

* Image Usage & Resolution